MaxCyte, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $136.0M
- Price
- $1.38
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.36%
- Volume
- 435.9K
About
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Quick stats
Shares outstanding107.1M
Computed float96.7M
Float / shares90.2%
Cash runway (months)2.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001287098
Websitehttps://www.maxcyte.com
AI Summary
AI-generated1/10
standardbullishproduct launch
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte launched the CHANGE-seq-BE and ONE-seq-BE off-target nomination assays, available through its SeQure service to support the development of genome editing therapies.
These assays provide sensitive identification of off-target sites for base editors (ABEs and CBEs), helping developers align with recent FDA guidance on genome safety and regulatory expectations.
CEO Maher Masoud noted that the addition of these orthogonal assays helps developers build stronger data packages for clinical development by better understanding and mitigating off-target risks.